Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: A multicenter study

Toyoaki Uchida, Shiro Baba, Akira Irie, Shigehiro Soh, Naoya Masumori, Taiji Tsukamoto, Hiroomi Nakatsu, Hiroyuki Fujimoto, Tadao Kakizoe, Takeshi Ueda, Tomohiko Ichikawa, Nobutaka Ohta, Tadaichi Kitamura, Makoto Sumitomo, Masamichi Hayakawa, Teiichiro Aoyagi, Masaaki Tachibana, Ryusuke Ikeda, Kohji Suzuki, Nobuo TsuruKazuo Suzuki, Seiichiro Ozono, Kiyohide Fujimoto, Yoshihiko Hirao, Kohichi Monden, Yasutomo Nasu, Hiromi Kumon, Kazuhiko Nishi, Shoichi Ueda, Hirofumi Koga, Seiji Naitoh

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We report a multicenter trial with transrectal high-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer. A total of 72 consecutive patients with stage Tlc-2NOMO prostate cancer were treated using the Sonablate 500™ HIFU device (Focus Surgery, Indianapolis, USA). Biochemical recurrence was defined according to the criteria recommended by the American Society for Therapeutic Radiology and Oncology Consensus Panel. The median age and prostate specific antigen (PSA) level were 72 years and 8.10 ng/ml, respectively. The median follow-up period for all patients was 14.0 months. Biochemical disease-free survival rates in all patients at 1 and 2 years were 78% and 76%, respectively. Biochemical disease-free survival rates in patients with stage Tie, T2a and T2b groups at 2 years were 89, 67% and 40% (p = 0.0817). Biochemical disease-free survival rates in patients with Gleason scores of 2-4, 5-7 and 8-10 at 2 years were 88, 72% and 80% (p = 0.6539). Biochemical disease-free survival rates in patients with serum PSA of less than 10 ng/ml and 10-20 ng/ml were 75% and 78% (p = 0.6152). No viable tumor cells were noted in 68% of patients by postoperative prostate needle biopsy. Prostatic volume was decreased from 24.2 ml to 14.0 ml at 6 months after HIFU (p

Original languageEnglish
Pages (from-to)651-658
Number of pages8
JournalActa Urologica Japonica
Volume51
Issue number10
Publication statusPublished - Oct 2005

Fingerprint

Transrectal High-Intensity Focused Ultrasound
Multicenter Studies
Prostatic Neoplasms
Disease-Free Survival
Survival Rate
Prostate-Specific Antigen
Therapeutics
Neoplasm Grading
Needle Biopsy
Prostate
Recurrence

Keywords

  • High-intensity focused ultrasound
  • Minimally invasive surgery
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Uchida, T., Baba, S., Irie, A., Soh, S., Masumori, N., Tsukamoto, T., ... Naitoh, S. (2005). Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: A multicenter study. Acta Urologica Japonica, 51(10), 651-658.

Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer : A multicenter study. / Uchida, Toyoaki; Baba, Shiro; Irie, Akira; Soh, Shigehiro; Masumori, Naoya; Tsukamoto, Taiji; Nakatsu, Hiroomi; Fujimoto, Hiroyuki; Kakizoe, Tadao; Ueda, Takeshi; Ichikawa, Tomohiko; Ohta, Nobutaka; Kitamura, Tadaichi; Sumitomo, Makoto; Hayakawa, Masamichi; Aoyagi, Teiichiro; Tachibana, Masaaki; Ikeda, Ryusuke; Suzuki, Kohji; Tsuru, Nobuo; Suzuki, Kazuo; Ozono, Seiichiro; Fujimoto, Kiyohide; Hirao, Yoshihiko; Monden, Kohichi; Nasu, Yasutomo; Kumon, Hiromi; Nishi, Kazuhiko; Ueda, Shoichi; Koga, Hirofumi; Naitoh, Seiji.

In: Acta Urologica Japonica, Vol. 51, No. 10, 10.2005, p. 651-658.

Research output: Contribution to journalArticle

Uchida, T, Baba, S, Irie, A, Soh, S, Masumori, N, Tsukamoto, T, Nakatsu, H, Fujimoto, H, Kakizoe, T, Ueda, T, Ichikawa, T, Ohta, N, Kitamura, T, Sumitomo, M, Hayakawa, M, Aoyagi, T, Tachibana, M, Ikeda, R, Suzuki, K, Tsuru, N, Suzuki, K, Ozono, S, Fujimoto, K, Hirao, Y, Monden, K, Nasu, Y, Kumon, H, Nishi, K, Ueda, S, Koga, H & Naitoh, S 2005, 'Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: A multicenter study', Acta Urologica Japonica, vol. 51, no. 10, pp. 651-658.
Uchida T, Baba S, Irie A, Soh S, Masumori N, Tsukamoto T et al. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: A multicenter study. Acta Urologica Japonica. 2005 Oct;51(10):651-658.
Uchida, Toyoaki ; Baba, Shiro ; Irie, Akira ; Soh, Shigehiro ; Masumori, Naoya ; Tsukamoto, Taiji ; Nakatsu, Hiroomi ; Fujimoto, Hiroyuki ; Kakizoe, Tadao ; Ueda, Takeshi ; Ichikawa, Tomohiko ; Ohta, Nobutaka ; Kitamura, Tadaichi ; Sumitomo, Makoto ; Hayakawa, Masamichi ; Aoyagi, Teiichiro ; Tachibana, Masaaki ; Ikeda, Ryusuke ; Suzuki, Kohji ; Tsuru, Nobuo ; Suzuki, Kazuo ; Ozono, Seiichiro ; Fujimoto, Kiyohide ; Hirao, Yoshihiko ; Monden, Kohichi ; Nasu, Yasutomo ; Kumon, Hiromi ; Nishi, Kazuhiko ; Ueda, Shoichi ; Koga, Hirofumi ; Naitoh, Seiji. / Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer : A multicenter study. In: Acta Urologica Japonica. 2005 ; Vol. 51, No. 10. pp. 651-658.
@article{63553f6d75114e479e34408ead57c309,
title = "Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: A multicenter study",
abstract = "We report a multicenter trial with transrectal high-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer. A total of 72 consecutive patients with stage Tlc-2NOMO prostate cancer were treated using the Sonablate 500™ HIFU device (Focus Surgery, Indianapolis, USA). Biochemical recurrence was defined according to the criteria recommended by the American Society for Therapeutic Radiology and Oncology Consensus Panel. The median age and prostate specific antigen (PSA) level were 72 years and 8.10 ng/ml, respectively. The median follow-up period for all patients was 14.0 months. Biochemical disease-free survival rates in all patients at 1 and 2 years were 78{\%} and 76{\%}, respectively. Biochemical disease-free survival rates in patients with stage Tie, T2a and T2b groups at 2 years were 89, 67{\%} and 40{\%} (p = 0.0817). Biochemical disease-free survival rates in patients with Gleason scores of 2-4, 5-7 and 8-10 at 2 years were 88, 72{\%} and 80{\%} (p = 0.6539). Biochemical disease-free survival rates in patients with serum PSA of less than 10 ng/ml and 10-20 ng/ml were 75{\%} and 78{\%} (p = 0.6152). No viable tumor cells were noted in 68{\%} of patients by postoperative prostate needle biopsy. Prostatic volume was decreased from 24.2 ml to 14.0 ml at 6 months after HIFU (p",
keywords = "High-intensity focused ultrasound, Minimally invasive surgery, Prostate cancer",
author = "Toyoaki Uchida and Shiro Baba and Akira Irie and Shigehiro Soh and Naoya Masumori and Taiji Tsukamoto and Hiroomi Nakatsu and Hiroyuki Fujimoto and Tadao Kakizoe and Takeshi Ueda and Tomohiko Ichikawa and Nobutaka Ohta and Tadaichi Kitamura and Makoto Sumitomo and Masamichi Hayakawa and Teiichiro Aoyagi and Masaaki Tachibana and Ryusuke Ikeda and Kohji Suzuki and Nobuo Tsuru and Kazuo Suzuki and Seiichiro Ozono and Kiyohide Fujimoto and Yoshihiko Hirao and Kohichi Monden and Yasutomo Nasu and Hiromi Kumon and Kazuhiko Nishi and Shoichi Ueda and Hirofumi Koga and Seiji Naitoh",
year = "2005",
month = "10",
language = "English",
volume = "51",
pages = "651--658",
journal = "Acta Urologica Japonica",
issn = "0018-1994",
publisher = "Editorial Board of Acta Urologica Japonica",
number = "10",

}

TY - JOUR

T1 - Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer

T2 - A multicenter study

AU - Uchida, Toyoaki

AU - Baba, Shiro

AU - Irie, Akira

AU - Soh, Shigehiro

AU - Masumori, Naoya

AU - Tsukamoto, Taiji

AU - Nakatsu, Hiroomi

AU - Fujimoto, Hiroyuki

AU - Kakizoe, Tadao

AU - Ueda, Takeshi

AU - Ichikawa, Tomohiko

AU - Ohta, Nobutaka

AU - Kitamura, Tadaichi

AU - Sumitomo, Makoto

AU - Hayakawa, Masamichi

AU - Aoyagi, Teiichiro

AU - Tachibana, Masaaki

AU - Ikeda, Ryusuke

AU - Suzuki, Kohji

AU - Tsuru, Nobuo

AU - Suzuki, Kazuo

AU - Ozono, Seiichiro

AU - Fujimoto, Kiyohide

AU - Hirao, Yoshihiko

AU - Monden, Kohichi

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

AU - Nishi, Kazuhiko

AU - Ueda, Shoichi

AU - Koga, Hirofumi

AU - Naitoh, Seiji

PY - 2005/10

Y1 - 2005/10

N2 - We report a multicenter trial with transrectal high-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer. A total of 72 consecutive patients with stage Tlc-2NOMO prostate cancer were treated using the Sonablate 500™ HIFU device (Focus Surgery, Indianapolis, USA). Biochemical recurrence was defined according to the criteria recommended by the American Society for Therapeutic Radiology and Oncology Consensus Panel. The median age and prostate specific antigen (PSA) level were 72 years and 8.10 ng/ml, respectively. The median follow-up period for all patients was 14.0 months. Biochemical disease-free survival rates in all patients at 1 and 2 years were 78% and 76%, respectively. Biochemical disease-free survival rates in patients with stage Tie, T2a and T2b groups at 2 years were 89, 67% and 40% (p = 0.0817). Biochemical disease-free survival rates in patients with Gleason scores of 2-4, 5-7 and 8-10 at 2 years were 88, 72% and 80% (p = 0.6539). Biochemical disease-free survival rates in patients with serum PSA of less than 10 ng/ml and 10-20 ng/ml were 75% and 78% (p = 0.6152). No viable tumor cells were noted in 68% of patients by postoperative prostate needle biopsy. Prostatic volume was decreased from 24.2 ml to 14.0 ml at 6 months after HIFU (p

AB - We report a multicenter trial with transrectal high-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer. A total of 72 consecutive patients with stage Tlc-2NOMO prostate cancer were treated using the Sonablate 500™ HIFU device (Focus Surgery, Indianapolis, USA). Biochemical recurrence was defined according to the criteria recommended by the American Society for Therapeutic Radiology and Oncology Consensus Panel. The median age and prostate specific antigen (PSA) level were 72 years and 8.10 ng/ml, respectively. The median follow-up period for all patients was 14.0 months. Biochemical disease-free survival rates in all patients at 1 and 2 years were 78% and 76%, respectively. Biochemical disease-free survival rates in patients with stage Tie, T2a and T2b groups at 2 years were 89, 67% and 40% (p = 0.0817). Biochemical disease-free survival rates in patients with Gleason scores of 2-4, 5-7 and 8-10 at 2 years were 88, 72% and 80% (p = 0.6539). Biochemical disease-free survival rates in patients with serum PSA of less than 10 ng/ml and 10-20 ng/ml were 75% and 78% (p = 0.6152). No viable tumor cells were noted in 68% of patients by postoperative prostate needle biopsy. Prostatic volume was decreased from 24.2 ml to 14.0 ml at 6 months after HIFU (p

KW - High-intensity focused ultrasound

KW - Minimally invasive surgery

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=28244454219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244454219&partnerID=8YFLogxK

M3 - Article

C2 - 16285617

AN - SCOPUS:28244454219

VL - 51

SP - 651

EP - 658

JO - Acta Urologica Japonica

JF - Acta Urologica Japonica

SN - 0018-1994

IS - 10

ER -